Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene ( (AU:IMU) ) has provided an announcement.
Imugene Limited has announced the quotation of additional securities on the Australian Securities Exchange (ASX), with a total of 532,182 ordinary fully paid shares being issued. This move reflects the company’s ongoing efforts to strengthen its financial position and enhance its market presence, potentially impacting its operational capabilities and investor confidence.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited operates in the biotechnology industry, focusing on the development of immuno-oncology therapies. The company specializes in creating innovative cancer treatments that harness the immune system to target and eradicate tumors, aiming to improve patient outcomes in the oncology market.
Average Trading Volume: 629,188
Technical Sentiment Signal: Sell
Current Market Cap: A$82.4M
For an in-depth examination of IMU stock, go to TipRanks’ Overview page.